389 related articles for article (PubMed ID: 22213216)
41. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
42. Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk.
El-Zein R; Monroy CM; Etzel CJ; Cortes AC; Xing Y; Collier AL; Strom SS
Cancer; 2009 Apr; 115(8):1651-9. PubMed ID: 19280628
[TBL] [Abstract][Full Text] [Related]
43. Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.
Slyskova J; Naccarati A; Pardini B; Polakova V; Vodickova L; Smerhovsky Z; Levy M; Lipska L; Liska V; Vodicka P
Mutagenesis; 2012 Mar; 27(2):225-32. PubMed ID: 22294771
[TBL] [Abstract][Full Text] [Related]
44. XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
Guillem VM; Cervantes F; Martínez J; Alvarez-Larrán A; Collado M; Camós M; Sureda A; Maffioli M; Marugán I; Hernández-Boluda JC
Am J Hematol; 2010 Jul; 85(7):482-6. PubMed ID: 20575039
[TBL] [Abstract][Full Text] [Related]
45. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
[TBL] [Abstract][Full Text] [Related]
46. Promoter polymorphisms in DNA repair gene ERCC5 and susceptibility to gastric cancer in Chinese.
Duan Z; He C; Gong Y; Li P; Xu Q; Sun LP; Wang Z; Xing C; Yuan Y
Gene; 2012 Dec; 511(2):274-9. PubMed ID: 22982416
[TBL] [Abstract][Full Text] [Related]
47. Modulation of DNA damage by XPF, XPG and ERCC1 gene polymorphisms in pesticide-exposed agricultural workers of Punjab, North-West India.
Kaur K; Kaur R
Mutat Res Genet Toxicol Environ Mutagen; 2021; 861-862():503302. PubMed ID: 33551103
[TBL] [Abstract][Full Text] [Related]
48. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
49. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
[TBL] [Abstract][Full Text] [Related]
50. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
51. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
[TBL] [Abstract][Full Text] [Related]
52. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
[TBL] [Abstract][Full Text] [Related]
53. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
54. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
55. Nucleotide excision repair pathway genes and oral premalignant lesions.
Wang Y; Spitz MR; Lee JJ; Huang M; Lippman SM; Wu X
Clin Cancer Res; 2007 Jun; 13(12):3753-8. PubMed ID: 17575242
[TBL] [Abstract][Full Text] [Related]
56. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand.
Kietthubthew S; Sriplung H; Au WW; Ishida T
Int J Hyg Environ Health; 2006 Jan; 209(1):21-9. PubMed ID: 16373199
[TBL] [Abstract][Full Text] [Related]
57. Association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and risk of cancer: a meta-analysis.
He XF; Liu LR; Wei W; Liu Y; Su J; Wang SL; Shen XL; Yang XB
PLoS One; 2014; 9(5):e88490. PubMed ID: 24802942
[TBL] [Abstract][Full Text] [Related]
58. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma.
Blankenburg S; König IR; Moessner R; Laspe P; Thoms KM; Krueger U; Khan SG; Westphal G; Volkenandt M; Neumann C; Ziegler A; Kraemer KH; Reich K; Emmert S
Eur J Hum Genet; 2005 Feb; 13(2):253-5. PubMed ID: 15494739
[TBL] [Abstract][Full Text] [Related]
59. The Role of DNA Repair (
Crișan AS; Tripon F; Bogliș A; Crauciuc GA; Trifa AP; Lázár E; Macarie I; Gabor MR; Bănescu C
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541232
[No Abstract] [Full Text] [Related]
60. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
Kong J; Liu Z; Cai F; Xu X; LiuI J
Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
